Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH lifted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1,328.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 219,222 shares of the medical instruments supplier's stock after acquiring an additional 203,873 shares during the quarter. Becton, Dickinson and Company makes up approximately 1.9% of Siemens Fonds Invest GmbH's holdings, making the stock its 9th largest holding. Siemens Fonds Invest GmbH owned about 0.08% of Becton, Dickinson and Company worth $49,735,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $25,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares during the last quarter. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. Picton Mahoney Asset Management raised its position in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Hopwood Financial Services Inc. bought a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $39,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Richard Byrd sold 459 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now directly owns 6,952 shares in the company, valued at $1,598,960. This represents a 6.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,878 shares of company stock valued at $636,393. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 0.7%

Shares of BDX traded down $1.29 during trading hours on Friday, reaching $172.53. The stock had a trading volume of 3,358,673 shares, compared to its average volume of 1,939,853. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The firm has a 50-day moving average of $192.64 and a 200 day moving average of $216.74. The company has a market cap of $49.45 billion, a P/E ratio of 28.66, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $3.17 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.41%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's payout ratio is presently 79.39%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BDX shares. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a research report on Friday, May 2nd. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $221.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.